Business Context and Reporting Period
Company: Eyegate Pharmaceuticals, Inc. (Note: Request metadata listed "Kiora," but filing text confirms "Eyegate Pharmaceuticals, Inc.")
Reporting Period: Quarter ended March 31, 2015
Business Overview: A clinical-stage specialty pharmaceutical company focused on developing therapeutics for eye diseases. The primary product candidate is EGP-437, a reformulated corticosteroid delivered via the proprietary EyeGate II Delivery System.
Key Event: The Company completed its Initial Public Offering (IPO) on February 13, 2015, issuing 683,250 shares at $6.00 per share. Concurrently, all outstanding convertible preferred stock and promissory notes were converted to common stock.
Key Financial Metrics
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,801,086) | $(902,892) |
| Net Loss Attributable to Stockholders | $(11,028,271) | $(961,840) |
| Cash and Cash Equivalents (End of Period) | $2,285,184 | $523,738 |
| Operating Cash Flow | $(1,768,950) | $(431,098) |
| Financing Cash Flow | $3,856,956 | $446,151 |
| Total Assets | $2,547,064 | $1,406,470 |
| Accumulated Deficit | $(59,668,415) | $(56,862,152) |
Debt and Liquidity: As of March 31, 2015, the Company had no outstanding convertible notes or preferred stock following the IPO conversions. Current liabilities totaled $412,745, primarily accounts payable and accrued expenses. The Company holds $20,000 in restricted cash.
Material Changes vs. Prior Period
- Capital Structure Transformation: The most significant change was the IPO and the subsequent conversion of all Series A, B, C, and D preferred stock, as well as all convertible promissory notes, into common stock. This eliminated $43.2 million in temporary equity and $3.2 million in convertible notes from the balance sheet.
- Loss Magnitude: Net loss attributable to stockholders increased significantly to $(11.0) million from $(0.96) million. This was driven by an $8.2 million "deemed dividend" recorded upon the conversion of preferred stock at a discount to the IPO price, and a $1.66 million non-cash interest expense related to the beneficial conversion feature of the notes.
- Operating Expenses: Total operating expenses rose to $1.1 million from $0.87 million. Research and Development (R&D) increased by $103,571 due to the ramp-up of Phase III clinical trials. General and Administrative (G&A) expenses increased by $126,630, largely due to stock-based compensation related to the IPO.
- Liquidity: Cash balances increased by over $2.1 million, primarily due to $4.1 million in gross IPO proceeds.
Outlook, Risks, and Management Commentary
- Going Concern: Management states that the Company has incurred operating losses since inception and anticipates future losses. While the IPO provided capital, the Company explicitly states that current cash resources are insufficient to fund operations for the next twelve months. Additional financing is required to continue development.
- Regulatory Progress: In a subsequent event (May 2015), the FDA provided positive feedback regarding the design of the planned Phase 3 trial for EGP-437 in anterior uveitis, indicating that data from this trial, combined with prior Phase 3 data, would be sufficient to support a New Drug Application (NDA).
- Risk Factors:
- Capital Needs: Failure to raise additional capital could force the Company to delay or terminate product development.
- Internal Controls: The Company identified material weaknesses in internal controls, including a lack of experienced accounting personnel and inadequate segregation of duties (e.g., one individual handling checks, payroll, and the general ledger).
- Legal Contingency: The Company failed to file FBAR reports for 2011 and 2012. While delinquent returns were filed in 2014, potential penalties remain a contingency, though management believes significant penalties are unlikely.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise, as management explicitly states current funds do not cover the next 12 months.
- Internal Control Remediation: Review subsequent filings to confirm if the material weaknesses in internal controls (specifically regarding segregation of duties and accounting expertise) have been addressed.
- Phase 3 Trial Status: Confirm the enrollment and progress of the Phase 3 trial for EGP-437, which is critical for the upcoming NDA filing.
- FBAR Penalty Status: Monitor for any updates regarding the potential penalties for the 2011-2012 FBAR filing omissions.
- Dilution: Assess the impact of the 1.15 million outstanding stock options and 637,980 warrants on future share count and ownership dilution.